A Double-Blind, Controlled Study to Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects

Trial Profile

A Double-Blind, Controlled Study to Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs ATB 346 (Primary) ; Naproxen
  • Indications Intestinal cancer; Malignant melanoma; Pain; Periodontal disorders
  • Focus Adverse reactions; Proof of concept
  • Sponsors Antibe Therapeutics
  • Most Recent Events

    • 28 Nov 2017 According to an Antibe Therapeutics media release, 97 subjects have been enrolled till date.
    • 20 Oct 2017 According to an Antibe Therapeutics media release, the company will discuss data from this trial with several regional pharmaceutical companies in 2017 CPhI Worldwide conference
    • 08 Sep 2017 According to an Antibe Therapeutics media release, the company announced that the first eight subjects have been enrolled and are on treatment in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top